Although it is well established that depression is a major risk factor for the development of coronary artery disease and that cerebrovascular disease can be a major contributing factor for the development of depression, the information about the interplay between the central nervous system and cardiovascular disease is still limited. We investigated the angiotensin I converting enzyme (ACE) ID and the G-protein ␤3-subunit (G␤3) C825T polymorphism in 201 patients with unipolar major depression and 161 ethnically and age-matched controls. Both gene variants have earlier been associated with either cardiovascular disease or affective disorders, making them good candidates for a combined analysis. We found a significant increase in the G␤3 T allele (OR = 1.61, 95% CI 1.17-2.2, P = 0.0035) and a marginal altered genotype distribution of the ACE ID polymorphism with decrease in the II genotypes ( 2 = 6.43, df=3, P = 0.04) in the patients' group. Analysing the data for both genes we found that the combined actions of ACE and G␤3 genotypes accumulate in carriers of the ACE D allele (ID and DD) and G␤3 TT homozygotes with ID/DD-TT carriers showing a more than five-fold increase in risk for major depression (crude OR = 5.83, 95% CI 1.99-17.08, P = 0.0002). As our study was carried out with depressive patients without serious cardiac impairment at the time of the investigation, we are presently unable to predict whether this combined action of the ACE ID/DD-G␤3 TT genotype is increasing the risk for both disorders. Nevertheless our study reports for the first time that the same allelic combination of two genes that have been shown to increase the risk for myocardial infarction (Naber et al, 2000) increase the vulnerability for depressive disorder.
There is burgeoning literature on the relationship between mood disorders and cardiovascular disease (CVD) . Several studies have demonstrated that depression increases the risk of developing cardiac disease, in particular coronary artery disease, and to worsen prognosis after myocardial infarction. 1 The impact of depression was mostly related to the premorbid cardiac disease status with a two-to four-fold increased risk of mortality during the first 6 months following myocardial infarction, 2 but its influence among persons being initially free of cardiac symptoms was discussed with controversy and mainly regarded to be smaller in subjects without pre-existing cardiac disease. The effects of major and minor depression on cardiac mortality were investigated in a recent study with a large community-dwellings sample of older subjects with and without cardiac disease. 3 The important finding of this study was that depression increases the risk for cardiac mortality independently from the baseline cardiac status and further, the excess mortality risk was more than twice as high for major depression as for minor depression. Besides the influence of depression on cardiovascular parameters it is now established that cerebrovascular disease also contributes to more or less pronounced cerebral lesions thereby predisposing to depression . 4, 5 Although the interaction of both disorders is clinically well documented, the mechanisms underlying this association are not elucidated up to now. Dysregulations in the autonomic system with elevation of plasma norepinephrine and heart rate as well as decreased heart rate variability or platelet abnormalities were repeatedly reported as candidate mechanisms underlying this association. 1, 6 The identification of neuroendocrine alterations in major depression might reflect pathological changes that are relevant to the increased vulnerability of depressed patients to CVD. Many studies have documented evidence of hypothalamic-pituitary-adrenocortical (HPA) axis hyperactivity in patients with major depression, which in the majority of the patients result in altered regulation of corticotropin (ACTH) and cortisol secretory activity. More refined analyses of the HPA system revealed that corticosteroid receptor (CR) signaling is impaired in major depression, resulting in increased production and secretion of corticotropin-releasing-hormone (CRH) in various brain regions. 7 As it is further known that administered corticosteroids induce hypercholesterinaemia, hypertriglyceridaemia and hypertension and that elevated morning cortisol concentrations were correlated with coronary artherosclerosis, 8 a relation between depression and CVD seems plausible.
A further link between both disorders could be the genes encoding for components of the renin-angiotensin system which have been investigated as candidates for hypertension or myocardial infarction 10 and also affective disorders. 11 The evidence about an involvement of the brain renin-angiotensin system in regulation of mood is based on several observations, as eg the co-localisation of angiotensin with dopamine synthesising neurones, 12 the fact that angiotensin converting enzyme (ACE) is involved in the metabolism of the neuropeptide substance P, which in turn is supposed to play a role in depression, 13 as well as the clinical observation that the application of ACE inhibitors in hypertensives might induce euphoric or depressive states. 14, 15 Further, an animal study with angiotensinogen-deficient mice showed a reduction in depressive-like behaviour. 16 These observations were underlined by an association study reporting an overrepresentation of the angiotensin I converting enzyme (ACE) DD genotype in patients with affective disorders.
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Several studies have demonstrated that ACE might also be involved in HPA axis regulation via the angiotensin II (ATII) generation. This evidence includes the presence of ATII-AT1 receptors in neurones of the hypothalamic paraventricular nucleus (PVN) containing CRH and vasopressin, the stimulatory effect of ATII on CRH mRNA and rapid changes in AT1 receptor expression and catecholamine production, 17, 18 These findings indicate that endogenous ATII in the brain is involved in regulation of CRH expression and required for sympathoadrenal activation during stress.
The ACE I/D polymorphism is characterised by the presence (I) or absence (D) of a 287-bp alu repeat sequence within intron 16 of the ACE gene, and the D allele is associated with increased levels of circulating ACE. 19 ACE is involved in blood pressure regulation via the angiotensin-renin cascade, generating angiotensin II (ATII) from angiotensin I. Numerous studies have implicated the ACE DD genotype with cardiovascular disorders, including myocardial infarction due to artherosclerosis, hypertension and left ventricular hypertrophy, but the associations were not consistent in all studies. A review of the literature revealed a moderate degree of increased risk for myocardial infarction associated with the ACE DD genotype in most populations, especially Japanese ones. 20 Recently the impact of the ACE DD genotype on myocardial infarction was re-evaluated using the paradigm of gene-gene interaction between the ACE gene variants together with a polymorphism (C825T) in the G-protein ␤3 subunit (G␤3) in patients with coronary artery disease with and without myocardial infarction. 21 The C825T variant in exon 10 of the G␤3 gene was earlier shown to be associated with the occurrence of a splice variant (G␤3-s) which leads to the deletion of 41 amino acids. This G␤3-s variant was not only associated with hypertension but also with increased signal transduction and ion transport. 22 In the combined analysis of the ACE and G␤3 polymorphisms, the highest odds ratio (OR = 7.5) was found in homozygous G␤3 825T carriers with the ACE DD genotype, 21 suggesting a significant interaction of the G␤3 825T and the ACE D Molecular Psychiatry allele as a possible contributing factor for myocardial infarction.
Based on the available literature and on our own previous results concerning an association of the G␤3 825T allele with affective disorders 23 and a possible influence of the ID polymorphism of the ACE gene polymorphism on therapeutic outcome in affective disorders, 24 we studied the interaction of both gene variants in 201 patients with unipolar major depression and 161 ethnically matched controls. Neither in patients nor in controls was there severe cardiac impairment, eight of the patients and four of the controls were known hypertensives (repeated blood pressure measurements above 140/90 mmHg). They were treated with blood-pressure lowering medication and normotensives at the time of blood sampling. As the influence of the ACE I/D polymorphism on essential hypertension is still under discussion with increased frequency of the I/I homozygotes among hypertensive persons 25 or no association, 26 we did not exclude those patients and controls from the study.
Patients and controls differed in gender distribution with an overrepresentation of females (64%) among patients. In contrast to that, there was no significant difference in age among both groups (t-test: F = 0.294, P = 0.46; Table 1 ). The individuals of both groups were comparable with respect to common cardiovascular risk factors, such as cigarette smoking, total cholesterol, triglyceride, fasting glucose, blood pressure or body mass index (Table 1) and there was no significant association between any of the genotypes and the risk factors.
ACE genotypes and the risk for major depression
In this study the OR related to the ACE-D allele was not significantly increased in patients with major depression (Table 2 : OR = 1.1; P = 0.29). However, we observed an increase in ID genotypes in the patient group (56.2%) as compared to controls (44.7%) which was compensated for by a decreased frequency of II homozygosity (16.9% vs 26.7%). Concerning clinical parameters such as age of onset, number of episodes or HAMD score, we found no significant interactions with the DD genotypes compared to II or ID carriers. Although the differences in genotypes were of marginal significance ( 2 = 6.43; df = 2; P = 0.040), these results are generally in agreement with our earlier finding in a sample of 90 patients with major depression 24 and with recent findings in the literature, where no increased frequency of DD carriers could be observed in patients with affective disorders. 27, 28 We could thus not replicate earlier results obtained with Japanese patients, where both the frequency of allele D and the DD genotype were increased in patients with affective disorders. 11 Gender differences among the samples might not be the reason for these discrepant results as in both groups the genotype distribution was not different (controls: 2 = 0.61, df = 2, P = 0.74; patients: 2 = 1.02, df = 2, P = 0.59). One explanation might be 
G-protein ␤3 (G␤3) C825T polymorphism
In a preliminary investigation with 88 patients we have found an increased frequency of the 825T allele in affective psychosis. 23 In this study using an extended sample of 201 patients with major depression we were able to replicate our previous results of an increased frequency of the T-allele of the G␤3 C825T polymorphism (OR = 1.6; P = 0.003) and a different genotype distribution with an increase in TT homozygotes ( 2 = 14.8; df = 2; P = 0.0006) ( Table 2 ). Thus our results are consistent with the hypothesis that disturbances in the signal transduction cascade on the level of G-proteins are involved as a contributing factor in the pathophysiology of major depression. As the 825T allele was associated with hypertension, 22 one might argue that an increased proportion of hypertensives among the patients might be the reason for this increase in the 825T allele frequency and TT carriers, this however could not be the reason, as four of the controls and eight of the patients were currently being treated with antihypertensive drugs, all others were normotensive. As with the ACE polymorphims we observed no significant interaction between genotypes and basic clinical parameters and no interaction with gender (patients: 2 = 1.64, df = 2, P = 0.44; controls 2 = 0.53, df = 2, P = 0.76).
Combined analysis
The complex and probably polygenic nature of both disturbances, CVD and depression, implies that interactions of various candidate genes are substantial to increase the risk for the disorders. Therefore we have carried out a stratified analysis with respect to the G␤3 genotypes to study the effects of the ACE D allele on the effects of G␤3-825TT genotypes. Table 3 shows the genotype distributions for both polymorphisms. The combined action of ACE and G␤3 genotypes accumulates in carriers of the ACE D allele (ID and DD) and G␤3 TT homozygotes (Figure 1 ) with ID/DD-TT carriers showing a more than five-fold increase in risk for major depression (crude OR = 5.83, 95% CI 1.99-17.08, P = 0.0002). The possible risk factors of age and gender did not reduce the OR when controlled in a logistic regression analysis. The OR for the G␤3 T-allele frequency alone was only 1.61 ( Table 2 ). The effects seems to be an accumulation of two independent effects, not a true functional interaction, since the independent effects of the two genes alone can explain the total variance almost completely (Table 4) . As these combined alleles are present only in a subset of patients one might argue that this genotype represents a subgroup of depression. Calculating basic clinical data in relation to the ID/DD-TT genotypes vs the combined other genotypes, we could not observe any difference among the two groups in age or the pretreatment Hamilton Depression Score (see Table 5 ). Concerning age of onset which was in the range of 16-75 years for ID/DD-TT carriers and 18-80 years in the other combined genotypes we could not find a significant difference between groups (P = 0.56). This assures that the ID/DD-TT genotype is not just representing older patients with possible vascular disturbances. With the cardiovascular risk factors, in ID/DD-TT carriers we found a tendency towards increased concentrations of total cholesterol (P = 0.066) and similarly a tendency towards a higher systolic blood pressure (P = 0.085), but no differences concerning triglyceride, fasting glucose, the diastolic blood pressure or the body mass index (Table 5 ). Further, in 21.2% of the ID/DD-TT carriers and in 23.8% of the combined genotypes, it was the first manifestation of the disease ( 2 = 0,102, df = 1, P = 0.75), thus the first episode patients were equally distributed over both groups. Our data do not suggest that the patients with the ID/DD-TT genotype are significantly different concerning their psychiatric and physical status. However, the so far available data do not preclude that there are differences in cardiovascular status between the groups and further investigations including imaging methods or neuropsychological testing will be necessary to discriminate between groups and especially to exclude possible underlying cerebrovascular diseases that might lead to depression.
The results of this study underline the hypothesis that two functional genetic variants can interact significantly in combined analysis to a given phenotype. On the basis of an already shown and now replicated interaction between the G␤3 825T allele and depression, an independent influence of each genetic factor could be one explanation. The activation of the HPA axis and the sympathetic nervous system via ATII and AT1 receptors during response to stress and the burgeoning literature supporting the hypothesis that impaired central stress 18 hormone regulation is causally involved in the development and course of depression, 7 suggest an involvement of the brain reninangiotensin system in the vulnerability for depression. Although to date it is not established with certainty whether both ACE and ATII are increased in ACE allele D carriers, 29 it was shown, that ACE inhibition also reduces basal and CRH stimulated ACTH levels, which in turn are modulated by ATII levels. 30 The fact that the literature is controversial with respect to the involvement of the ACE I/D polymorphism in genetic vulnerability to depression 11 could propose that other, maybe genetic variants are necessary for the expression of the phenotype.
G-proteins are essential regulatory components of the transmembrane signaling to the intracellular effector systems and are increasingly discussed as being important in the pathophysiological mechanism for the Molecular Psychiatry disorder and as a target for antidepressant medication. 31 So far the majority of the investigations in affective disorders were carried out with the G␣-subunit, but at present there is no evidence that alteration in the level and function of G␣s, as is often observed in functional studies, is caused by mutations in the G␣s gene itself. 32 We could not only observe an increased frequency of the 825T allele of the G␤3 polymorphism in patients with depression but also a more rapid response to treatment in TT carriers, which might be explained by more rapidly occurring adaptive changes in this genotype with increased signal transduction. 23 A combined action of the two systems could be explained on the observation that hormones of the renin-angiotensin system, which is affected by the ACE I/D polymorphism, activate G-protein coupled receptors, whose signaling properties may be altered by the G␤3 C825T polymorphism. It was shown, that G-protein␤␥ subunits play a role in modulating the affinity of AT1 receptors 33 and that ATII increases the expression of pertussis toxin-sensitive G-proteins 34 whose signaling properties are enhanced in the presence of a G␤3 825T allele. 22 In this context it seems of importance that platelet function abnormalities were observed in both disorders. Platelets play a central role in homeostasis and CVD via multiple interactions with endothelial vessel walls and plasma coagulation factors. 35 Due to their expression of several neurotransmitter receptors and selective uptake proteins they are also frequently used as a model for central neurones.
1 Several studies have demonstrated altered 5-HT2A-and ␣2-receptor density and reactivity in depressed patients and a significantly increased elevation of intracellular calcium after serotonergic stimulation. 36 Elevated plasma concentration of epinephrine and serotonin, which have been reported in depressed patients, or even increased blood flow might thus trigger altered platelet function and increased aggregation 1 and thus predispose depressed patients to clotting diathesis. 1 In this context it is of importance, that genetic variants were also shown to alter aggregation, as in platelets obtained from carriers of the G␤3 825T allele, the slopes and maximum of secondary aggregation were significantly enhanced after epinephrine challenge. 37 This phenomenon appeared independent of platelet secretion or inhibition of the adenylylcyclase and may suggest that this enhanced reactivity might also increase platelet reactivity in vivo.
A limitation of this investigation is that we confined our analysis to patients with unipolar major depression without serious cardiac impairment at the time of the investigation. Thus we are presently unable to predict whether the combined action of the ACE ID+ DD/G␤3 TT genotype increases the risk for both disorders. Future studies will have to focus on patients with cardiovascular disease and depression, to include imaging data as well as neuropsychological testing in order to clarify the impact of this finding on the clinically observed and well described interactions. In conclusion, our study reports for the first time that the same allelic combination of two genes that have been shown to increase the risk for myocardial infarction 21 also increases the vulnerability for unipolar depression. Thus our data might be suggestive of an interaction of both disorders due to a genetically induced vulnerability. Future studies in the field of gene-gene and gene-environment interactions will be helpful in predicting an individual's risk for depression and the comorbidity with other, serious physical disturbances.
Methods

Patients and controls
A total of 362 persons were genotyped for the ACE I/D and the G␤3-C825T polymorphisms. Two hundred and one unrelated Caucasian patients with major depression (72 males, 128 females), hospitalised because of severity of the disorder, were recruited in the Psychiatric Department of University Munich (for demographic characteristics see Table 1 ). Diagnoses were made according to DSM-IV and ICD-10 criteria by two independent psychiatrists. Patients comprised the following DSM-IV categories: 296.2x n = 48; 296.3x n = 153. Psychiatric ratings included the Hamilton rating scale for depression (HAM-D17) and the clinical global impression scale (CGI, Item 1-severity of disease). None of the patients had severe cardiac impairment, eight of them were hypertensives being under blood pressure lowering drugs, all other were normotensives.
One hundred and sixty-one ethnically matched subjects from the general population in Southern Germany (75 males, 86 females, mean age 48 ± 13 years) served as a control group. All probands have been screened psychiatrically using the OPCRIT 3.3 checklist. Probands with a known history of psychiatric disorders, including drug abuse, in the index probands themselves and their first degree relatives have been excluded from the study. Four of the Controls were under continuous antihypertensive medication. All the others had no history of any cardiovascular disturbances.
The study was approved by the local Ethic Committee of the University, patients and probands gave informed and written consent to participate in the study.
Genotyping
Blood samples (5 ml) were taken from patients and controls and DNA was extracted according to standard procedures. Genotyping of the G␤3 C825T polymorphism was carried out as previously described. 22, 23 The ACE gene insertion/deletion was investigated using a modified method of Rigat, 29 taking into account a possible mistyping with false increased frequency of DD homozygotes (MgCl 2 1.5 mmol l −1 ; addition of 7-deazaGTP, 50 mol l −1 ; DMSO 5%). All laboratory procedures were carried out blind to case-control status.
Statistical analysis
Statistical analyses were carried out using the SSPS (Statistical Package for Social Science) Software, Version 10. The genotype distributions were tested by the 2 test for goodness-of-fit. Allele frequencies were compared between patients and the control group by using the two-sided Fisher's Exact Test. The influence of gender and age was controlled by a logistic regression analysis. To disentangle the various sources of variance in the three-dimensional data cube presented by the combined ACE and G␤3 genotypes of patients and controls, the chi 2 -partitioning method of Lancaster 38 (1951) was used.
